Fiche centre
The First People's Hospital of Changzhou
Changzhou — China
Essais liés3clinical trials
VilleChangzhoulocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05410925
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Recombinant staphylokinase | Maladie coronarienne | Phase 4 | NCT05410925 | OPTIMA-6 — Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction | RECRUITING |
| Amivantamab | Cancer | Phase 3 | NCT04538664 | PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | ACTIVE_NOT_RECRUITING |
| Penpulimab | Cancer | Non applicable | NCT07764601 | RM-MA-PD1 — R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma | NOT_YET_RECRUITING |